ARDS is a rapidly progressing, severe lung disease commonly encountered in intensive care units (ICU) which makes breathing difficult or impossible. It can be caused by many different triggers, including sepsis, pneumonia, and trauma. It is characterized by widespread injury of the alveolar–capillary membrane, resulting in protein rich noncardiogenic pulmonary edema (fluid accumulation in the lungs) and acute respiratory failure (ARF). ARDS results in severe hypoxemia, which is refractory to oxygen treatment and requires assisted ventilation.
Respirogen OMB technology will provide systemic oxygen independent from the damaged lungs, reducing ventilator dependency and the need for Extracorporeal Membrane Oxygenation (ECMO).
Multiple additional research opportunities have been identified for development of OMB therapies: